"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 7 | 2 | 9 |
| 2003 | 13 | 5 | 18 |
| 2004 | 6 | 5 | 11 |
| 2005 | 2 | 7 | 9 |
| 2006 | 4 | 5 | 9 |
| 2007 | 14 | 1 | 15 |
| 2008 | 11 | 5 | 16 |
| 2009 | 8 | 4 | 12 |
| 2010 | 14 | 8 | 22 |
| 2011 | 16 | 2 | 18 |
| 2012 | 14 | 4 | 18 |
| 2013 | 8 | 6 | 14 |
| 2014 | 6 | 4 | 10 |
| 2015 | 3 | 4 | 7 |
| 2016 | 11 | 4 | 15 |
| 2017 | 5 | 3 | 8 |
| 2018 | 13 | 5 | 18 |
| 2019 | 6 | 3 | 9 |
| 2020 | 5 | 7 | 12 |
| 2021 | 7 | 12 | 19 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.
-
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
-
Voriconazole-Induced Periostitis in a Transplant Patient. J Clin Rheumatol. 2022 Apr 01; 28(3):e671.
-
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
-
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan. Pediatr Neurosurg. 2022; 57(1):63-68.